Capricor shares drop after FDA issues complete response letter for lead DMD therapy

7 hours ago 2

Capricor Therapeutics (NASDAQ:CAPR) shares fell Friday after the company announced it received a complete response letter from the U.S. Food and Drug Administration for its Biologics License Application for Deramiocel, its lead cell therapy candidate for treating cardiomyopathy in Duchenne muscular

Recommended For You

More Trending News

Read Entire Article